Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:04 AM
Ignite Modification Date:
2025-12-25 @ 4:04 AM
NCT ID:
NCT05346302
Eligibility Criteria:
Inclusion Criteria:
* Ages 18-40 (inclusive)
* Subject is judged to be in satisfactory health based on medical history, physical examination
* Ability to walk, sit down and stand up independently
* Willingness and ability to comply with the protocol
* ownership and use of smartphone
* ownership and use of laptop
Exclusion Criteria:
* Subject has planned elective surgery requiring 2 or more days of hospitalization during the entire study
* Active dependence of alcohol or drugs (self-reported)
* Known allergy to any of the following:
* Components of the vaccine/placebo
* Diagnosed and active treatment of chronic disease:
* Diabetes (Type 1 or 2)
* Active malignancy
* Heart disease
* Kidney disease
* Liver disease
* HIV/AIDS
* Hepatitis A, B, or C
* Asthma (moderate to severe)
* (possible/desire to be) pregnancy (confirmed via urine pregnancy test)
* Subject is currently enrolled in a study with an investigational compound or device
* Subject has already received the pneumococcal (PPSV23) vaccine
* Subject has already received the typhoid (inactivated) vaccine
* Subject has received any other investigational vaccination within 4 weeks of enrollment
* Any other condition that interfere with the definition 'healthy" based on self-report and according to the PI/study physician's judgement based on medical history, use of medication, and physical exam.
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
40 Years
Study:
NCT05346302
Study Brief:
Protocol Section:
NCT05346302